Gening Jiang

机构：Shanghai University, Tongji University, Shanghai Pulmonary Hospital · ORCID：0000-0002-1351-3409

发表论文 547 篇 · 总被引 12032 次 · h-index 53

代表论文

• Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II–III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study (2024 · Signal Transduction and Targeted Therapy · 被引 35)
• Expert consensus on the multidisciplinary diagnosis and treatment of multiple ground glass nodule-like lung cancer (2024 Edition) ∆ (2024 · Journal of Cancer Research and Therapeutics · 被引 18)
• Insights into the heterogeneity of the tumor microenvironment in lung adenocarcinoma and squamous carcinoma through single‐cell transcriptomic analysis: Implications for distinct immunotherapy outcomes (2024 · The Journal of Gene Medicine · 被引 16)
• Neoadjuvant Aumolertinib for unresectable stage III EGFR-mutant non-small cell lung cancer: a single-arm phase II trial (2025 · Nature Communications · 被引 15)
• Tumor therapeutics in the era of “RECIST”: past, current insights, and future prospects (2024 · Oncology Reviews · 被引 13)
• Spatiotemporally Controlled Co-Treatment of Lung Cancer and Pulmonary Immune-Related Adverse Events by Inhalable Albumin-Chaperoned Ultrathin MnO 2 Nanosheets (2025 · ACS Nano · 被引 12)